Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.64)
# 195
Out of 5,139 analysts
141
Total ratings
52.42%
Success rate
41.41%
Average return
Main Sectors:
Stocks Rated by Mayank Mamtani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRD Opus Genetics | Initiates: Buy | $9 | $2.10 | +328.57% | 1 | Dec 10, 2025 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $33 → $42 | $22.20 | +89.19% | 2 | Dec 1, 2025 | |
| ZYME Zymeworks | Reiterates: Buy | $30 → $40 | $23.47 | +70.43% | 2 | Nov 21, 2025 | |
| NUVB Nuvation Bio | Initiates: Buy | $12 | $5.85 | +105.13% | 1 | Nov 19, 2025 | |
| NVAX Novavax | Reiterates: Buy | $18 → $16 | $8.01 | +99.75% | 20 | Nov 10, 2025 | |
| CYTK Cytokinetics | Reiterates: Buy | $80 → $90 | $62.58 | +43.82% | 5 | Nov 10, 2025 | |
| HROW Harrow | Reiterates: Buy | $70 → $74 | $47.90 | +54.49% | 4 | Oct 1, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $460 → $560 | $501.68 | +11.62% | 13 | Sep 29, 2025 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $85 → $105 | $37.68 | +178.66% | 3 | Sep 23, 2025 | |
| TGTX TG Therapeutics | Maintains: Buy | $53 → $55 | $30.57 | +79.91% | 14 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $20.01 | +39.93% | 1 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $5.80 | +245.13% | 1 | Aug 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $18 | $4.24 | +324.53% | 10 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.60 | +212.50% | 2 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $3 | $1.72 | +74.42% | 2 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $2.5 → $2 | $0.71 | +182.69% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 → $20 | $10.48 | +90.84% | 3 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.70 | +76.47% | 2 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 → $35 | $17.99 | +94.55% | 2 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $51 → $38 | $63.84 | -40.48% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $109 → $96 | $33.92 | +183.02% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1 → $1.5 | $1.46 | +2.74% | 3 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $11.34 | +1,134.57% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $90 | $3.69 | +2,339.02% | 5 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $3.34 | +4,690.42% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $5 | $1.81 | +176.24% | 3 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $44 | $2.04 | +2,056.86% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $90 | $3.72 | +2,319.35% | 4 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $7 | $1.73 | +304.62% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9,750 → $4,500 | $1.05 | +428,471.43% | 3 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5,000 → $2,700 | $1.21 | +223,966.39% | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $138 → $77 | $7.29 | +956.24% | 2 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,980 → $1,440 | $0.77 | +186,646.21% | 3 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $3.04 | +31.58% | 2 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $39 | $89.28 | -56.31% | 2 | Mar 18, 2020 |
Opus Genetics
Dec 10, 2025
Initiates: Buy
Price Target: $9
Current: $2.10
Upside: +328.57%
Centessa Pharmaceuticals
Dec 1, 2025
Maintains: Buy
Price Target: $33 → $42
Current: $22.20
Upside: +89.19%
Zymeworks
Nov 21, 2025
Reiterates: Buy
Price Target: $30 → $40
Current: $23.47
Upside: +70.43%
Nuvation Bio
Nov 19, 2025
Initiates: Buy
Price Target: $12
Current: $5.85
Upside: +105.13%
Novavax
Nov 10, 2025
Reiterates: Buy
Price Target: $18 → $16
Current: $8.01
Upside: +99.75%
Cytokinetics
Nov 10, 2025
Reiterates: Buy
Price Target: $80 → $90
Current: $62.58
Upside: +43.82%
Harrow
Oct 1, 2025
Reiterates: Buy
Price Target: $70 → $74
Current: $47.90
Upside: +54.49%
Madrigal Pharmaceuticals
Sep 29, 2025
Maintains: Buy
Price Target: $460 → $560
Current: $501.68
Upside: +11.62%
Nektar Therapeutics
Sep 23, 2025
Maintains: Buy
Price Target: $85 → $105
Current: $37.68
Upside: +178.66%
TG Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $53 → $55
Current: $30.57
Upside: +79.91%
Sep 12, 2025
Initiates: Buy
Price Target: $28
Current: $20.01
Upside: +39.93%
Aug 26, 2025
Initiates: Buy
Price Target: $20
Current: $5.80
Upside: +245.13%
Aug 13, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $4.24
Upside: +324.53%
Jun 16, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $1.60
Upside: +212.50%
May 20, 2025
Maintains: Neutral
Price Target: $5 → $3
Current: $1.72
Upside: +74.42%
Mar 27, 2025
Maintains: Buy
Price Target: $2.5 → $2
Current: $0.71
Upside: +182.69%
Mar 19, 2025
Reiterates: Buy
Price Target: $11 → $20
Current: $10.48
Upside: +90.84%
Mar 14, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $1.70
Upside: +76.47%
Mar 5, 2025
Reiterates: Buy
Price Target: $38 → $35
Current: $17.99
Upside: +94.55%
Feb 14, 2025
Reiterates: Buy
Price Target: $51 → $38
Current: $63.84
Upside: -40.48%
Feb 7, 2025
Reiterates: Buy
Price Target: $109 → $96
Current: $33.92
Upside: +183.02%
Dec 19, 2024
Upgrades: Buy
Price Target: $1 → $1.5
Current: $1.46
Upside: +2.74%
Oct 13, 2023
Initiates: Buy
Price Target: $140
Current: $11.34
Upside: +1,134.57%
Apr 10, 2023
Maintains: Buy
Price Target: $210 → $90
Current: $3.69
Upside: +2,339.02%
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $3.34
Upside: +4,690.42%
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $1.81
Upside: +176.24%
Aug 11, 2022
Maintains: Buy
Price Target: $58 → $44
Current: $2.04
Upside: +2,056.86%
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $3.72
Upside: +2,319.35%
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $1.73
Upside: +304.62%
Jan 24, 2022
Maintains: Buy
Price Target: $9,750 → $4,500
Current: $1.05
Upside: +428,471.43%
Nov 30, 2021
Maintains: Buy
Price Target: $5,000 → $2,700
Current: $1.21
Upside: +223,966.39%
Jan 15, 2021
Downgrades: Neutral
Price Target: $138 → $77
Current: $7.29
Upside: +956.24%
May 22, 2020
Downgrades: Neutral
Price Target: $1,980 → $1,440
Current: $0.77
Upside: +186,646.21%
Apr 3, 2020
Maintains: Buy
Price Target: $8 → $4
Current: $3.04
Upside: +31.58%
Mar 18, 2020
Maintains: Buy
Price Target: $47 → $39
Current: $89.28
Upside: -56.31%